Доктор ли Капитула

[Kapitula]

Я сама пока не нашла где почитать. Как нибудь пораспрашиваю того типа, кто мне про него сказала.
А моя мам глюкозамин пьет постоянно. Говорит, как начала пить, у нее ноги не так сильно болят. Сын тоже сказал, что у него суставы стали меньше болеть. А я эффекта не замечаю.
Мне кажется, что глюкозамин просто оттягивает на себя антитела и они меньше аттакуют свои собственные клетки. Нодо бы покопатсы в литературе

так я про него и говорила, что 3 месяца советуют. больше - нет.

[larsen]

это не таме для порнозвезд, да. здесь интеллектуалы собираются

eto ty?
semejnik

[Kapitula]

eto ty?
semejnik

slozhno perevodit' to, chto ty ne mozhesh' na translit nazhat'
no ty poprobuj, pornozvezda
chsaj odna knopka vsego, mozhet osilish'

[larsen]

slozhno perevodit' to, chto ty ne mozhesh' na translit nazhat'
no ty poprobuj, pornozvezda
chsaj odna knopka vsego, mozhet osilish'

dear semejnik!!!!
translit u menja ne rabotaet bolee 8 mesjacev
dazhe admin ob etom znaet

[Kapitula]

деар семейник!!!!
транслит у меня не работает более 8 месяцев
даже админ об етом знает

щас нажму

[Kapitula]

а. так ты скажи им, пусть сделаыт.
на моем експлорере глючит, потом починяют. и ничего

[microb]

из того что я читала, советуют 3 месяца. после этого макс достигнут.
с татрациклином интересно, где бы что почитать, или расскажи?

Нашла про тетрациклин. Даже можно всю статью скачать

http://www.ncbi.nlm.nih.gov/pubmed/24403843
Int J Gen Med. 2014; 7: 43–47.
Published online Dec 27, 2013. doi: 10.2147/IJGM.S56957
PMCID: PMC3883615
Antibiotics for the treatment of rheumatoid arthritis
Mesut Ogrendik

There have been four double-blind, randomized clinical studies published regarding the use of minocycline for the treatment of RA.4–7 The first study was carried out in the Netherlands on 80 long-term (disease course >10 years) RA patients who had not benefitted from more than one disease-modifying antirheumatic drug (DMARD). In this randomized controlled study, patients were treated with placebo or minocycline (200 mg per day) in addition to their previous drug regime, for 6 months.4 The second published study was conducted by the Minocycline in RA (MIRA) group. This study was carried out for 1 year and investigated 219 moderate RA patients who did not respond to one or more DMARD. The patients discontinued use of DMARDs during the study.5 The other two studies were conducted by the Rheumatoid Arthritis Investigational Network (RAIN).6,7 The four trials showed that minocycline is indeed efficacious in the treatment of RA. When the long-term effects were studied, it was found that the minocycline was still effective during the second year of the treatment.7

[Kapitula]

знаю, что у этих антибиотиков еще и антивоспалительный эфект, но! у тебя же не РА, значит все не относитса?

[microb]

знаю, что у этих антибиотиков еще и антивоспалительный эфект, но! у тебя же не РА, значит все не относитса?

а ревматоидный артрит относится к аутоиммунным заболеваниям?

[microb]

Вот еше одна статья, совсем свеженькая:

Br J Pharmacol. 2013 May;169(2):337-52. doi: 10.1111/bph.12139.
Minocycline: far beyond an antibiotic.
Garrido-Mesa N1, Zarzuelo A, Gálvez J.

Minocycline is a second-generation, semi-synthetic tetracycline that has been in therapeutic use for over 30 years because of its antibiotic properties against both gram-positive and gram-negative bacteria. It is mainly used in the treatment of acne vulgaris and some sexually transmitted diseases. Recently, it has been reported that tetracyclines can exert a variety of biological actions that are independent of their anti-microbial activity, including anti-inflammatory and anti-apoptotic activities, and inhibition of proteolysis, angiogenesis and tumour metastasis. These findings specifically concern to minocycline as it has recently been found to have multiple non-antibiotic biological effects that are beneficial in experimental models of various diseases with an inflammatory basis, including dermatitis, periodontitis, atherosclerosis and autoimmune disorders such as rheumatoid arthritis and inflammatory bowel disease. Of note, minocycline has also emerged as the most effective tetracycline derivative at providing neuroprotection. This effect has been confirmed in experimental models of ischaemia, traumatic brain injury and neuropathic pain, and of several neurodegenerative conditions including Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, Alzheimer's disease, multiple sclerosis and spinal cord injury. Moreover, other pre-clinical studies have shown its ability to inhibit malignant cell growth and activation and replication of human immunodeficiency virus, and to prevent bone resorption. Considering the above-mentioned findings, this review will cover the most important topics in the pharmacology of minocycline to date, supporting its evaluation as a new therapeutic approach for many of the diseases described herein.